Experience of treatment of hairy cell leukemia with new drug Vero-cladribine

Yu. E. Ryabukhina; Рябухина Ю. Е.; A. D. Shirin; Ширин А. Д.; O. L. Timofeeva; Тимофеева О. Л.; N. N. Tupitsyn; Тупицын Н. Н.; M. A. Frenkel; Френкель М. А.; N. A. Kupryshina; Купрышина Н. А.; M. A. Volkova; Волкова М. А.

doi:10.17650/1818-8346-2007-0-1-31-37

Experience of treatment of hairy cell leukemia with new drug Vero-cladribine

Authors: Ryabukhina Y.E.¹, Shirin A.D.¹, Timofeeva O.L.¹, Tupitsyn N.N.¹, Frenkel M.A.¹, Kupryshina N.A.¹, Volkova M.A.¹
Affiliations:
1. N.N. Blokhin Russian Cancer Research Centre, Russian Academy of Medical Sciences
Issue: No 1 (2007)
Pages: 31-37
Section: THERAPY OF HEMATOLOGIC MALIGNANCIES
Published: 22.02.2007
URL: https://oncohematology.abvpress.ru/ongm/article/view/617
DOI: https://doi.org/10.17650/1818-8346-2007-0-1-31-37
ID: 617

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Between July 2005and October 2006, eight patients (pts) with hairy cell leukaemia were treated with Vero- cladribine at N.N. Blokhin Cancer Research Center. All pts achieved complete remission (CR). Duration of CR ranges from 1+ to 12+ months in 7 cases. There were no serious adverse events during the treatment and follow-up periods (1-12 months). Vero- cladribine was well tolerated. Anemia (grade IV) was seen in 1 patient and thrombocytopenia (grade I) was seen in another 1 patient. No one patient has febrile neutropenia or infectious complication.